Amneal completed its acquisition of Kashiv BioSciences, adding end-to-end biosimilar R&D, manufacturing, and commercialization capabilities.
The deal creates a fully integrated biosimilars platform, positioning biosimilars as a long-term growth pillar within Amneal’s Affordable Medicines business.
The combined business targets an expected surge in biologic loss of exclusivity, citing more than $300 billion of projected global opportunities over the next decade.
Integration work is underway, focused on combining development and manufacturing operations while advancing the biosimilar pipeline.
AMRX•
